Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| Market is closed on Tue. Aug. 17, 2021 | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 0% (three month average) | RSI | | Latest Price | $(0%) | Stocks Behave Similarly | Similar Stock List | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) IBB(18%) XBI(18%) IPO(15%) ARKG(14%) KWEB(14%) | Factors Impacting TNXP price | TNXP will advance at least -0% in a week (0% probabilities). XME(-13%) IFRA(-11%) SLV(-9%) SIL(-9%) XLB(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | 0% (StdDev 0%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY. July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |